oaioai:doaj.org/article:cfc07cf740c74aac92b452c16fc6f65f

Colistin use in critically ill neonates: A caseâcontrol study

Abstract

Background: The aim of this study was to assess the safety and efficacy of colistin use in critically ill neonates. Methods: This was a caseâcontrol study that included newborn infants with proven or suspected nosocomial infections between January 2012 and October 2015, at two centers in Diyarbakir, Turkey. The clinical and laboratory characteristics and outcomes of patients who received colistin therapy were reviewed and compared to patients who were treated with antimicrobial agents other than colistin during the same period. Results: Forty-seven cases who received intravenous colistin (colistin group) and 59 control patients (control group) were included. There were no significant differences between the groups regarding outcomes and nephrotoxicity, including acute renal failure. Colistin therapy was associated with significantly reduced serum magnesium (1.38 ± 0.39 mg/dL vs. 1.96 ± 0.39 mg/dL, p < 0.001) and hypokalemia (46.8% vs. 25.4%, p = 0.026). The patients who received colistin also had longer hospital stays (43 (32â70) days vs. 39 (28â55) days, p = 0.047), a higher rate of previous carbapenem exposure (40.4% vs. 11.9%, p = 0.001), and a higher age at the onset of infection (13 (10â21) days vs. 11 (9â15) days, p = 0.03). Conclusion: This study showed that colistin was both effective and safe for treating neonatal infections caused by multidrug-resistant gram-negative bacteria. However, intravenous colistin use was significantly associated with hypomagnesemia and hypokalemia. Key Words: colistin, neonate, nosocomial infection, multi-drug resistant, gram-negative bacteri

Similar works

Full text

thumbnail-image

Directory of Open Access Journals

Provided original full text link
oaioai:doaj.org/article:cfc07cf740c74aac92b452c16fc6f65fLast time updated on 12/17/2017

This paper was published in Directory of Open Access Journals.

Having an issue?

Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.